1Meta-AnalysisCited 250×2015
Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C · J Clin Endocrinol Metab (2015)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
87 peer-reviewed studies
What the evidence says
Pramlintide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1997–2026 with a typical study size of 3,297 participants.
Based on 87 studies · 5 meta-analyses · 65 RCTs · 3,297 total participants
Confidence
High confidenceBy outcome
23 studies in the last 5 years · Latest meta-analysis: 2021
Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C · J Clin Endocrinol Metab (2015)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Singh-Franco D, Perez A, Harrington C · Diabetes Obes Metab (2011)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Avgerinos I, Manolopoulos A, Michailidis T, Kitsios K, Liakos A, Karagiannis T · Diabetes Obes Metab (2021)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D · Diabetes Obes Metab (2003)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: These suggestions aim to determine whether RAS inhibition enhances the overall efficacy of amylin-based therapies, and whether RAS blockers should be strongly recommended in patients receiving them.
Muskiet MHA, Nardone M, Rensen PCN, Cherney DZI, Cooper ME. · Lancet (London, England) (2026)
In plain English: In this narrative review, we summarized the current evidence and ongoing studies on the mechanism of action, clinical pharmacology, and applications of amylin and its analogs, pramlintide and cagrilintide, in the field of diabetology, endocrinology, and metabolism disorders, such as obesity.
Eržen S, Tonin G, Jurišić Eržen D, Klen J. · International journal of molecular sciences (2024)
In plain English: We discuss the potential and challenges of developing amylin-based treatments for cardiometabolic disease, including milestones in drug development of amylin, and its combination with additional molecules as part of the future landscape of therapies for patients with diabetes or obesity.
Secher A, Lutz TA, Raun K. · Nature metabolism (2026)
In plain English: This Review describes how amylin controls energy homeostasis and provides a current overview of amylin-based therapeutic development.
Walker CS, Aitken JF, Vazhoor Amarsingh G, Zhang S, Cooper GJS. · Nature reviews. Endocrinology (2025)
Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R · Diabetes Obes Metab (2014)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K · Diabetes Care (2007)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Heise T, Heinemann L, Heller S, Weyer C, Wang Y, Strobel S · Metabolism (2004)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Lush CW · Obesity (Silver Spring) (2007)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Wysham C, Lush C, Zhang B, Maier H, Wilhelm K · Curr Med Res Opin (2008)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y · Diabetes Care (2003)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Hinshaw L, Schiavon M, Dadlani V, Mallad A, Dalla Man C, Bharucha A · J Clin Endocrinol Metab (2016)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Chase HP, Lutz K, Pencek R, Zhang B, Porter L · J Pediatr (2009)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Thompson RG, Pearson L, Kolterman OG · Diabetologia (1997)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C · Metabolism (2003)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Edelman SV, Darsow T, Frias JP · Int J Clin Pract (2006)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA · Clin Endocrinol (Oxf) (2016)
No plain-language summary recorded for this citation — open the paper to read its abstract.